tbuckley/cabot-search huggingface dataset:
Rhodamine123 reveals heterogeneity within murine Lin-, Sca-1+ hemopoietic stem cells.
Authors: C L Li, G R Johnson
Journal: The Journal of Experimental Medicine (1992)

Murine bone marrow Lin-, Ly6A/E+ cells have been fractionated on the basis of rhodamine123 retention into Rh123med/hi and Rh123lo subpopulations. These populations have different responses to hemopoietic growth factors with respect to in vitro colony formation. Cells from either fraction were not stimulated by only granulocyte-colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), interleukins 1 and 6 (IL-1 and -6), or leukemia inhibitory factor (LIF) alone. The Rh123med/hi, but not the Rh123lo fraction, contained cells that could be stimulated by either stem cell factor (SCF) or IL-3 alone. When combinations of growth factors were added, the Rh123med/hi fraction produced more colonies, and responded to a wider range of factor combinations than the Rh123lo population. When tested in vivo, both populations contained no detectable day 8 colony-forming unit-spleen (CFU-S), and similar frequencies of day 13 CFU-S. When transplanted into lethally irradiated recipients (100 cells/recipient), significant numbers of donor cells (67-73%) were found in the peripheral blood of Rh123lo recipients. Both myeloid and lymphoid cells were of donor origin. By comparison, the Rh123med/hi population produced recipients with 1-2% donor cells in peripheral blood, the majority of which were lymphoid.
John Stephen Hughes-Games
Authors: Ivor Doney
Journal: BMJ (2004)

Former general practitioner and homoeopathic physician Bristol (b 1927; q Bristol 1954; FFHom), died from leukaemia on 22 July 2004.​2004.




Figure 1




John's great passion was homoeopathic medicine. He was past president of the Faculty of Homoeopathic Medicine, a lecturer, author, and an examiner in faculty examinations, and he did regular phone-ins on local radio and cable television. He was a talented sketcher and painter, and enjoyed fishing and shooting. He leaves a wife, Sue; four children; and five grandchildren.
Cardiovascular diseases, oxidative stress and antioxidants: the decisive role of coenzyme Q10
Authors: E Bliznakov
Journal: Cardiovascular Research (1999)

Time for primary review 28 days. 

In his timely article [1], Dr. P.K. Singal reviews the relationship between oxidative stress, antioxidants and cardiac diseases. This field is the most extensively investigated area of cardiovascular research with consequential practical therapeutic ramifications. Unfortunately, the author’s presentation of the clinical effectiveness of various antioxidants in the prevention or restriction of the molecular, cellular and systems effects of oxidative stress is limited. An essential omission is the absence of any reference to the involvement and the well-studied clinical applications of coenzyme Q10 in various forms of cardiovascular diseases — a subject of great interest for the readers of this publication.

Coenzyme Q10 (CoQ10, ubiquinone) is a naturally occuring, fat-soluble nutrient (a quinone), with characteristics that are common to vitamins and, like vitamins, is essential to the optimal functioning of an organism. CoQ10 is a potent and versatile antioxidant that is present in humans and in some animals. In addition to its antioxidant function, CoQ10 plays an indispensable role in intracellular energy production. Being a vital electron and proton carrier, CoQ10 supports adenosine triphosphate synthesis in the mitochondrial inner membrane and stabilizes cell membranes, thus preserving cellular integrity and function. Most CoQ10 clinical research is focused on the large, heterogeneous …
Equine Chorionic Gonadotropin
Authors: BRUCE D. MURPHY, SUSAN D. MARTINUK
Journal: Endocrine Reviews (1991)

Cells from the chorionic girdle of the equine trophoblast invade the maternal endometrium at day 36 of gestation and become established as secretory elements known as the endometrial cups. These structures, which persist for 40-60 days, produce a gonadotropin which can be found in circulation until about day 130 of gestation. This glycoprotein has been identified in the horse and the donkey, with the former having received much better characterization. It consists of 2 noncovalently linked peptide chains; an alpha-subunit of 96 amino acids, which is common to that found in other horse glycoprotein hormones. The beta-subunit of 149 amino acids is identical to horse LH beta. Horse CG is the most heavily glycosylated of the known pituitary and placental glycoprotein hormones. The alpha-subunit has two and the beta-subunit one N-linked glycosylation site, and the beta-chain has in excess of four O-linked glycosylation sites. The N-linked glycans have some oligosaccharides that are not found on other glycoprotein hormones. The sialic component of glycosylation confers an exceptionally long half-life on CG compared to other glycoprotein hormones. Horse CG has LH-like activity in horse receptor and in vitro bioassays. In spite of the amino acid homology, it has lower LH activity than does horse LH. Its most intriguing, and as yet unexplained, characteristic is its pronounced FSH and LH activity in species other than the horse. Horse CG binds to FSH receptors of virtually all mammalian species, other than the horse, in which it has been tested and will produce biological effects peculiar to FSH. It has similar and potent interaction with LH receptors. The structural basis of this duality is not known but may be related to the region 90-110 of the beta-chain. Horse CG is believed to be constitutively expressed by the trophoblastic cells until the endometrial cups degenerate. The role of CG in equine gestation is not completely understood. It is believed to act as an LH-like hormone to induce supplementary ovulation and/or luteinization of follicles in the mare. It has not been established whether CG or the accessory corpora lutea are necessary for successful horse pregnancy. They may serve as a redundant system to assure that there is sufficient secretion of the primary corpus luteum to maintain pregnancy until the placenta assumes its role as the principal steroidogenic organ of gestation.
Primary Adult Human Astrocytes as an ex Vivo Vehicle for β-Glucuronidase Delivery in the Brain
Authors: Che Serguera, Chamsy Sarkis, Jean-Luc Ridet, Philippe Colin, Philippe Moullier, Jacques Mallet
Journal: Molecular Therapy (2001)

Astrocytes are a good candidate cell type for brain transplantation: They are endogenous to the CNS, they have efficient secretory machinery, and they play a major role in neuronal support. We assessed the potential of genetically modified primary adult human astrocytes as vehicles for the delivery of secreted molecules in the mammalian CNS. We report that such cells can be efficiently transduced by a recombinant adenoviral vector carrying the human beta-glucuronidase cDNA (Ad/CMV*beta-glu) and that the transduced astrocytes produce large amounts of the enzyme. Released beta-glucuronidase could be captured, in vitro, by primary neurons and astrocytes and by a neuroblastoma cell line and beta-glucuronidase-deficient fibroblasts. Following grafting into the mouse striatum, adult human astrocytes survived and expressed the transgene for at least 8 weeks. Moreover, the dosage of beta-glucuronidase activity within the grafted brains revealed high enzymatic levels at a long distance from the graft. These experiments document the grafting of engineered primary adult human astrocytes, allowing the release of a secreted therapeutic factor throughout the brain.
PDE isoenzymes as targets for anti-asthma drugs
Authors: C Schudt, H Tenor, A Hatzelmann
Journal: European Respiratory Journal (1995)

Phophodiesterase (PDE) isoenzyme profiles of human cell preparations and tissues have been analysed by a semiquantitative method using selective PDE inhibitors and activators. Neutrophils, eosinophils and monocytes contain PDE IV exclusively. Lymphocytes, alveolar macrophages and endothelial cells contain PDE IV and PDE III, and in addition, PDE I is measured in macrophages and PDE II in endothelial cells. These basal cell-specific PDE isoenzyme profiles appear to be modified by: 1) substrate concentration; 2) kinase-dependent phosphorylation; and 3) regulated rate of synthesis. Therefore, PDE isoenzyme profiles represent dynamic patterns, which apparently adapt to pathological and environmental conditions. In parallel functional studies, the influence of mono-selective (rolipram, PDE IV; motapizone, PDE III), dual-selective (zardaverine) and non-selective (theophylline) PDE inhibitors were compared. Corresponding to isoenzyme analysis, it was demonstrated that both PDE III and PDE IV have to be inhibited for complete suppression of either tumour necrosis factor-alpha (TNF-alpha) release from macrophages, or lymphocyte proliferation (PDE III/IV cells). In eosinophils (PDE IV cells) platelet-activating factor (PAF)-induced chemotaxis or C5a-stimulated degranulation are only weakly inhibited by rolipram alone. After addition of a beta 2-agonist, however, the efficacy of rolipram is enhanced due to concomitant influence of synthesis and breakdown of cyclic adenosine monophosphate (cAMP). Theophylline inhibits PDE isoenzyme activities and functions of inflammatory cells with similar potency, and exhibits higher functional efficacy as compared to rolipram.
Thrombolytic Therapy for Acute Stroke — Not a Moment to Lose
Authors: Patrick Lyden
Journal: New England Journal of Medicine (2008)

Stroke, the most common cause of disability in the world among adults, remains the only neurologic disorder for which physicians are potentially able to completely reverse disabling deficits.1 Thrombolytic therapy, which can restore neurologic functions if given early enough, not only has stood the test of time, shown benefit in serial community registries on multiple continents, and received approval by every major regulatory authority in the world, but also has now — once again — been shown in a randomized, blinded, placebo-controlled trial to be efficacious. The results of the European Cooperative Acute Stroke Study III (ECASS III)2 (ClinicalTrials.gov number, . . .
Response: Education and Responsibility
Authors: Michael McCann
Journal: Environmental Health Perspectives (1997)

sumers/users to comply with the supplied information.Safety assessment and risk communication is a dynamic process.Our knowledge base is constantly increasing, and society's interpretation ofwhat constitutes safety is an evolving process.As newer technology becomes available to better qualify and quantify the potential adverse effects of materials, safe and acceptable conditions for use become available and affordable for artists, whether their studios are located at homes, schools, or workplaces.Further, as toxicologists who certify compliance with LHAMA, we must reassess and recertify each unchanged art material every five years.Any changes that may have occurred in the product formulation or the state of knowledge since the initial certification are revisit- ed.In this way, new information and concerns for safety are added to our knowledge base and to the label.
Review: Insufficient evidence exists on the benefit of vitamin D in patients with chronic kidney disease not requiring dialysis
Authors: James B. Wetmore
Journal: Annals of Internal Medicine (2010)

ACP Journal Club20 April 2010Review: Insufficient evidence exists on the benefit of vitamin D in patients with chronic kidney disease not requiring dialysisJames B. Wetmore, MDJames B. Wetmore, MDUniversity of Kansas Medical Center, Kansas City, Kansas, USA (J.B.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-8-201004200-02012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationPalmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(4):CD008175. https://pubmed.ncbi.nlm.nih.gov/19821446Clinical Impact RatingsEndocrinology: Nephrology: References1 Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009;(4):CD005633. [PMID: 19821349] Google Scholar2 Hruska KA, Mathew S, Lund RJ, Memon I, Saab G. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2009;29:156-65. [PMID: 19371806] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Kansas Medical Center, Kansas City, Kansas, USA (J.B.W.)This article was published at Annals.org on 6 April 2010. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 April 2010Volume 152, Issue 8Page: JC4-12KeywordsBoneBone and mineral metabolismChronic kidney diseaseHistomorphometryHypercalcemiaMedical dialysisMortalityNephrologyRisk ratioVitamin D ePublished: 20 April 2010 Issue Published: 20 April 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Downregulation fof transthyretin-MET30 expression in cell culture with inosine15.1-hammerhead ribozymes
Authors: M.J. Pröpsting, J. Genschel, C. Büttner, S. Kubicka, P. Baier, M.P. Manns, H. Lochs, H.H.-J. Schmidt
Journal: Journal of Hepatology (2000)
Mortality experience in relation to a measured arsenic trioxide exposure
Authors: Sherman S. Pinto, Philip E. Enterline, Vivian Henderson, Michael O. Varner
Journal: Environmental Health Perspectives (1977)

This report examines the mortality experience of 527 men who retired from a copper smelter where they were exposed to airborne arsenic trioxide. Urinary arsenic values of all plant employees were determined in 1973, and the relative arsenic exposure in the various departments of the plant were determined. The relationship of airborne arsenic concentrations to urinary arsenic values was studied in a separate experiment, and the feasibility of using urinary arsenic values as a measure of arsenic exposure was established. The mortality experience of the cohort under study showed them to have a mortality 12.2% higher than was found for males of the same area at the same ages and in the same time period. The excess mortality was due chiefly to respiratory cancer. When the deaths were classified by total lifetime arsenic exposure, the respiratory cancer mortality was linearly related to the amount of exposure. The 1973 figures for arsenic exposure underestimated the exposure of the cohort group by a factor of possibly 10. Evidence was obtained which suggests that after removal from arsenic exposure, the risk of lung cancer declines. Certain of the data which are presented suggests there may be a threshold value for airborne arsenic trioxide exposure below which no adverse effects may be expected.
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
Authors: Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian, William G. Wierda
Journal: Blood (2011)
Disease management in Europe
Authors: T. Richards
Journal: BMJ (1998)

Can healthcare providers improve the cost effectiveness of patient care by contracting out chunks to pharmaceutical companies? The evidence is equivocal, but the experiment is under way as drug companies move into chronic disease management.

The theory is as follows. Systematic, integrated, evidence based, long term care of populations of patients with chronic, high cost diseases such as asthma, back pain, rheumatoid arthritis, dementia, and diabetes is more effective than episodic fragmented care of individuals. The incidence of acute episodes and complications associated with disease is reduced and quality of life improves.1 Better health outcomes reduce costs. Setting up “disease management” programmes that operate across the boundaries of primary, secondary, and community care requires high capital investment and state of the art information technology. Few health care providers can readily supply these. Pharmaceutical industries can. Hence the logic of contracting out services or setting up joint ventures.

The difference between shared care (as, for example, in diabetes and asthma in Britain), …
Doctors should be encouraged to talk to colleagues who make errors, group says
Authors: S. Mayor
Journal: BMJ (2013)

Healthcare organisations should encourage doctors to rethink their relationships with colleagues who make errors, encouraging them to raise problems directly rather than thinking that it is more supportive to keep quiet, recommends a US expert group in a report published this week.1

Existing guidelines emphasise the importance of disclosing errors that clinicians make themselves but offer little guidance on disclosing others’ mistakes. …
Northern Ireland signs deal for electronic patient records after successful pilot
Authors: M. Cross
Journal: BMJ (2012)

Northern Ireland is the latest part of the UK to commit to making patients’ care records available electronically across the NHS and social care sector. Under a £9m (€11.2; $14) contract signed on 29 May, 18 acute and community hospitals, all GP practices, and community and mental health units in the province will be connected with an electronic care record (ECR) system that displays patients’ data extracted from local information technology systems.

Health and Social Care Northern Ireland, the government department responsible for both health …
Clinical decision making: from theory to practice. Applying cost-effectiveness analysis. The inside story
Authors: D. M. Eddy
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunoadsorption for Removal of a and B Blood-Group Antibodies
Authors: William I. Bensinger, Don A. Baker, C. D. Buckner, Reginald A. Clift, E. Donnall Thomas
Journal: New England Journal of Medicine (1981)

ABO blood-group incompatibility between donor and recipient constitutes an obstacle to bone-marrow transplantation unless some method of removing the risk of hemolysis is used. Hemagglutinins in the recipient's plasma are capable of reacting with A or B antigens present on red cells in the donor's marrow. However, Gale1 and Buckner2 and their colleagues have carried out successful transplantations despite major ABO incompatibility by performing repeated plasma exchanges before infusing the marrow. This approach is effective but uses large quantities of a valuable blood product and exposes the recipient to additional risks of hepatitis and other transmissible disease. Thus, alternative methods . . .
Identifying Ga-67 Uptake in Brown Adipose Tissue WithSPECT/CT
Authors: Yung-Cheng Huang, Pei-Wen Wang, Shu-Wen Tang, Pi-Lien Hung, Chien-Chin Hsu
Journal: Clinical Nuclear Medicine (2009)

A 10-year-old boy complained of pain around his right hip for 3 weeks. He underwent Ga-67 scintigraphy to evaluate possible bone or joint infection. There was no pathologic Ga-67 uptake near the right hip; however, there was symmetrical Ga-67 uptake in his right and left upper chest. An immediate SPECT/CT scan showed radiotracer uptake in bilateral supraclavicular and subclavicular areas corresponding to the low-attenuation regions on CT as the common locations containing brown adipose tissue. Ga-67 uptake in brown adipose tissue is unusual. Integrated SPECT/CT is helpful for identifying this physiological Ga-67 uptake.
Abstract 1176: The expression of RN7SK paralogs in tumors of renal cell carcinoma is associated with patient survival
Authors: Xiaofan Zhang, Michelle A. Hildebrandt, Yohei Horikawa, Xia Pu, Christopher G. Wood, Jian Gu
Journal: Cancer Research (2011)

Abstract Purpose: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and also the most lethal type of genitourinary cancer. RN7SK RNA, a highly expressed non-coding RNA, was originally found to negatively regulate the transcription elongation factor P-TEFb, which can activate RNA polymerase II and pre-mRNA processing. Previous studies have shown the important role of this machinery in growth control and tumorigenesis. In human genome, eleven homologous non-coding RN7SK RNAs (http://www.noncode.org) have been speculated to possess similar function, but no experimental data have been reported. In this study, we determined the function of these RN7SK paralogs and evaluated their association with RCC development and prognosis. Experimental Design: Co-immunoprecipitation (Co-IP) was performed to determine the involvement of these RN7SK paralogs in the transcription elongation using antibody of LARP7, a RN7SK specific binding protein. Then, 114 paired tumor tissues and corresponding adjacent normal tissues from histologically confirmed RCC patients were used to measure the expression level of these predicted RN7SK RNAs by real-time PCR. Associations with overall survival, recurrence, and stage were analyzed with adjustment for age, gender, race, smoking status, family hypertension, and family history of cancer. Results: Co-IP results showed that eight of the eleven RN7SK paralogs were present in RN7SK ribonucleoprotein complex. Each detectable RN7SK RNA showed high expression level in both normal and tumor tissue, with significantly higher expression in tumor than in normal tissue except for n6233. High expression of n283 and n6233 was significantly associated with increased risk of death in RCC patients with hazard rations (HRs) of 3.23 (95% confidence interval [CI], 1.33-7.82; p=0.009) and 2.23 (95% CI; 1.03-4.79; p=0.041), respectively. Four other RN7SK paralogs were also significantly associated with survival, including n206 (p=0.022), n274 (p=0.037), n283 (p=0.007), and n6233 (p=0.014). No significant associations were identified for recurrence risk for any of the eight RN7SKRNAs. N133 (p=0.0005) and n139 (p=0.02) showed significantly different expression level between early (stage I&amp;II) and late stage (stage III&amp;IV) tumors. CONCLUSIONS: Our results suggest that RN7SK paralogs may be involved in RCC tumorigenesis and the expression of select RN7SK may be valuable biomarkers of RCC prognosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1176. doi:10.1158/1538-7445.AM2011-1176